(VIANEWS) – The Market ended the session with ERYTECH PHARMA (ERYP.PA) rising 12.52% to €0.89 on Thursday while CAC 40 rose 0.11% to €7,139.25.
ERYTECH PHARMA’s last close was €0.80, 64.82% under its 52-week high of €2.26.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-1.14.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ERYTECH PHARMA’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
ERYTECH PHARMA’s stock is valued at €0.89 at 21:32 EST, way under its 52-week high of €2.26 and way higher than its 52-week low of €0.29.
Moving Average
ERYTECH PHARMA’s worth is way above its 50-day moving average of €0.65 and higher than its 200-day moving average of €0.85.
More news about ERYTECH PHARMA (ERYP.PA).
